HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ACON

Aclarion, Inc. (NASDAQ)

Healthcare — Health Information Services

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

None 1 analysts
$2.88
$0.14 (-0.35%)
Target: $7.50 (160.4%)
Sign in to add ACON to a watchlist or set price alerts.

Price History

Fundamentals

Market Cap$7.44M
P/E Ratio (TTM)-
Forward P/E-0.55
EPS (TTM)$-5.63
Dividend Yield-
Profit Margin-
Revenue Growth-
ROE-
Debt/Equity-
Recommendation None
Analyst Target$7.50
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)34.0
Beta1.22
SMA 20-
SMA 40-
52-Week High-
52-Week Low-
50-Day Avg-
200-Day Avg-
Avg Volume-
Volume-

Performance Analysis

NEUTRAL

ACON presents a mixed picture with both positive and negative indicators.

~ RSI at 34.0 is in neutral territory.
~ Wall Street consensus is "none" from 1 analysts.
+ Average analyst target of $7.50 implies 160.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 01, 2026 11:46 UTC

Back to Screener Export Report